Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally. From Wikipedia
The experimental drug combines GLP-1 and amylin hormones, offering potential advances in obesity treatment.
